Search

Your search keyword '"Sendur, M.A."' showing total 38 results
Start Over Author "Sendur, M.A."
38 results on '"Sendur, M.A."'

1. 252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study

Author

Kahraman, S., primary, Seyyar, M., additional, Sahin, E., additional, Cabuk, D., additional, Gumusay, O., additional, Basaran, G., additional, Hizal, M., additional, Yasar, A., additional, Bayoglu, I.V., additional, Bayram, E., additional, Paydas, S., additional, Gulbagci, B., additional, Hacibekiroglu, I., additional, Demirel, B. Cakan, additional, Yaren, A., additional, Ozcelik, M., additional, Yılmaz, F., additional, Paksoy, N., additional, Aydiner, A., additional, and N. Sendur, M.A., additional

Published
2023
Full Text
View/download PDF

3. 99P The association between antibiotic use and survival in renal cell carcinoma patients treated with nivolumab: A multi-center study

Author

Guven, D.C., primary, Acar, R., additional, Yekeduz, E., additional, Bilgetekin, I., additional, Baytemur, N. Kose, additional, Erol, C., additional, Ceylan, F., additional, Sendur, M.A., additional, Demirci, U., additional, Urun, Y., additional, Karadurmus, N., additional, Erman, M., additional, and Kilickap, S., additional

Published
2020
Full Text
View/download PDF

4. Comparison of gemcitabine monotherapy with gemcitabine and cisplatin combination in metastatic pancreatic cancer: A retrospective analysis

Author

Ergun Y., Ozdemir N.Y., Guner E.K., Esin E., Sendur M.A., Koksoy E.B., Demirci N.S., and Zonguldak Bülent Ecevit Üniversitesi

Subjects
Metastatic pancreatic cancer, First-line therapy, Gemcitabine plus cisplatin
Abstract

Purpose: Gemcitabine is among the standard first-line agents for the treatment of metastatic pancreatic cancer. However, as the median survival with gemcitabine monotherapy is 6 months, different combinations are being studied for better, prolonged survival. In this multicenter study, we aimed to compare the results of gemcitabine monotherapy with those of gemcitabine and cisplatin combination therapy as first-line treatments for metastatic pancreatic cancer. Methods: Data of 664 patients diagnosed with metastatic pancreatic cancer between January 2007 and December 2016 from seven oncology centers in Turkey were retrospectively evaluated, and 319 patients with gemcitabine alone (n=138) or gemcitabine and cisplatin combination (n=181) as first-line treatment were included. Results: The median patient age was 62 years (range 42-79), being 60 years (42-75) in the gemcitabine/cisplatin arm and 67 years (52-79) in gemcitabine alone arm. no complete response was observed in either arm, whereas partial response rates were 30.1% in gemcitabine/cisplatin arm and 15.3% in gemcitabine alone arm (p=0.001). median overall survival was 8 months (95% CI:7.7–10.2) and was significantly longer in the gemcitabine/cisplatin arm than in the gemcitabine alone arm (10 vs. 6 months, p=0.004). Conclusion: The cemcitabine and cisplatin combination therapy as first-line treatment of metastatic pancreatic cancer yields significantly prolonged survival over gemcitabine monotherapy. In patients with favorable performance conditions, the combination therapy should be preferred. © 2018 Zerbinis Publications. All Rights Reserved.

Published
2018

6. P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Author

Kilickap, S., primary, Demirci, U., additional, Bugdayci, F., additional, Tural, D., additional, Korkmaz, T., additional, Paydas, S., additional, Yilmaz, C., additional, Turna, H., additional, Sezer, A., additional, Cinkir, H. Yesil, additional, Okutur, K., additional, Erman, M., additional, Eralp, Y., additional, Cabuk, D., additional, Isikdogan, A., additional, Demirkazik, A., additional, Karaoglu, A., additional, Yazilitas, D., additional, Senler, F. Cay, additional, Yumuk, P.F., additional, Coskun, H., additional, Yildiz, I., additional, Oztop, I., additional, Beypinar, I., additional, Aydin, K., additional, Kaplan, M., additional, Meydan, N., additional, Olmez, O.F., additional, Ozyilkan, O., additional, Seber, S., additional, Arslan, C., additional, Sendur, M.A., additional, and Cicin, I., additional

Published
2019
Full Text
View/download PDF

7. P84.03 GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

Author

Peled, N., Gillis, R., Kilickap, S., Froesch, P., Orlov, S., Filippova, E., Demirci, U., Christopoulos, P., Cicin, I., Bugdayci Basal, F., Yilmaz, C., Fedor, M., Korkmaz, T., Paydas, S., Gautschi, O., Zirtiloglu, A., Eralp, Y., Cinkir, H.Y., Sezer, A., Erman, M., Tural, D., Turna, H.Z., Mazieres, J., Dudnik, E., Reguart, N., Camidge, R., Ng, T.L., Senler, F. Cay, Beypınar, İ., Yazılıtaş, D., Demirkazik, A., Karaoğlu, A., Okutur, K., Şenol Coşkun, H., Nahit Şendur, M.A., Isikdogan, A., Cabuk, D., Yumuk, P.F., Yıldız, I., Kaplan, M.A., Özyılkan, Ö., Öztop, İ., Olmez, O.F., Aydin, K., Aydıner, A., Meydan, N., Grinberg, R., and Roisman, L.

Published
2021
Full Text
View/download PDF

9. P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey

Author

Kılıçkap, S., primary, Ozturk, A., additional, Karadurmuş, N., additional, Korkmaz, T., additional, Yumuk, P., additional, Çiçin, İ., additional, Paydaş, S., additional, Çılbır, E., additional, Sakalar, T., additional, Uysal, M., additional, Üskent, N., additional, Demir, N., additional, Sakin, A., additional, Turhal, N., additional, Keskin, S., additional, Tural, D., additional, Eralp, Y., additional, Basal, F., additional, Yaşar, H., additional, Sendur, M.A., additional, Demirci, U., additional, Çubukçu, E., additional, Karaağaç, M., additional, Karaca, Ş., additional, Tatlı, A., additional, Yetisyigit, T., additional, Urvay, S., additional, Gürsoy, P., additional, Oyan Uluç, B., additional, Turna, Z., additional, Kucukoner, M., additional, Ölmez, Ö., additional, Çabuk, D., additional, Şeker, M., additional, Ünal, O., additional, Meydan, N., additional, Okutur, S., additional, and Tunalı, D., additional

Published
2018
Full Text
View/download PDF

10. Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: Report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO)

Author

Aydin D., Sendur M.A., Kefeli U., Unal O.U., Tastekin D., Akyol M., Tanrikulu E., and Zonguldak Bülent Ecevit Üniversitesi

Subjects
Small bowel adenocarcinoma, Chemotherapy, Advanced, Prognostic factors
Abstract

Purpose: Small bowel adenocarcinoma (SBA) is a rare tumor of the gastrointestinal system with poor prognosis. Since these are rarely encountered tumors, there are limited numbers of studies investigating systemic treatment in advanced SBA. The purpose of this study was to evaluate the prognostic factors and systemic treatments in patients with advance SBA. Methods; Seventy-one patients from 18 Centers with advanced SBA were included in the study. Fifty-six patients received one of the four different chemotherapy regimens as first-line therapy and 15 patients were treated with best supportive care (BSC). Results: Of the 71 patients, 42 (59%) were male and 29 (41%) female with a median age of 56 years. Median follow-up duration was 14.3 months. The median progression free survival (PFS) and overall survival (OS) were 7 and 13 months, respectively (N=71). In patients treated with FOLFOX (N=18), FOLFIRI (N=ll), cisplatin-5-fluoroura-cil/5-FU (N=17) and gemcitabine alone (N=10), median PFS was 7, 8, 8 and 5 months, respectively; while median OS was 15, 16,15 and 11 months, respectively. No significant differences between chemotherapy groups were noticed in terms of PFS and OS. Univariate analysis revealed that chemotherapy administration, de novo metastatic disease, ECOG PS 0 and 1, and overall response to therapy were significantly related to improved outcome. Only overall response to treatment was found to be significantly prognostic in multivariate analysis (p= 0.001). Conclusions: In this study, overall response to chemotherapy emerged as the single significant prognostic factor for advanced SBAs. Platin and irinotecan based regimens achieved similar survival outcomes in advanced SBA patients.

Published
2016

23. Efficacy of Adjuvant 9-Weeks Trastuzumab in Node-Negative T1A/B Her2-Positive Breast Cancer

Author

Sendur, M.A., primary, Aksoy, S., additional, Uncu, D., additional, Demir, H., additional, Yuksel, S., additional, Ekinci, A.S., additional, Kaplan, M.A., additional, Ustaalioglu, B.B., additional, Tufan, G., additional, İnanc, M., additional, Ozdemir, N., additional, Artac, M., additional, Taştekin, D., additional, Kacan, T., additional, Oguz, A., additional, Arpaci, E., additional, Yazılıtas, D., additional, Gumus, M., additional, Zengin, N., additional, and Altundag, M.K., additional

Published
2014
Full Text
View/download PDF

38. Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO)

Author

Aydin, D., Mehmet Sendur, Kefeli, U., Unal, O. U., Tastekin, D., Akyol, M., Tanrikulu, E., Ciltas, A., Ustaalioglu, B. B., Dede, D. S., Esbag, O., Inal, A., Bilir, C., Bilici, A., Harputlu, H., Berk, V., Sevinc, A., Ozdemir, N. Y., Yildirim, E., Sonkaya, A., Ustaoglu, M. A., Gumus, M., Aydin, D., Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Semsi Denizer Street, Istanbul, 34890, Turkey, Sendur, M.A., Department of Medical Oncology, Numune Education and Research Hospital, Ankara, Turkey, Kefeli, U., Department of Medical Oncology, School of Medicine, Kocaeli University, Kocaeli, Turkey, Unal, O.U., Department of Medical Oncology, Faculty of Medicine, Dokuz EylulUniversity, Izmir, Turkey, Tastekin, D., Department of Medical Oncology, Faculty of Medicine, Selcuk University Meram, Konya, Turkey, Akyol, M., Department of Medical Oncology, Faculty of Medicine, Katip Celebi University, Izmir, Turkey, Tanrikulu, E., Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey, Ciltas, A., Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey, Ustaalioglu, B.B., Department of Medical Oncology, Haydar- Pasa Education and Research Hospital, Istanbul, Turkey, Dede, D.S., Department of Medical Oncology, Faculty of Medicine, Yildirim Beyazit University, Ankara, Turkey, Esbag, O., Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey, Inal, A., Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey, Bilir, C., Department of Medical Oncology, Faculty of Medicine, Karaelmas University, Zonguldak, Turkey, Bilici, A., Department of Medical Oncology, Faculty of Medicine, Medipol University, Istanbul, Turkey, Harputlu, H., Department of Medical Oncology, Faculty of Medicine, Inonu University, Malatya, Turkey, Berk, V., Department of Medical Oncology, Faculty of Medicine, Erciyes University, Kayseri, Turkey, Sevinc, A., Department of Medical Oncology, Faculty of Medicine Gaziantep University, Gaziantep, Turkey, Ozdemir, N.Y., Department of Medical Oncology, Numune Education and Research Hospital, Ankara, Turkey, Yildirim, E., Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Semsi Denizer Street, Istanbul, 34890, Turkey, Sonkaya, A., Department of Medical Oncology, School of Medicine, Kocaeli University, Kocaeli, Turkey, Ustaoglu, M.A., Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Semsi Denizer Street, Istanbul, 34890, Turkey, and Gumus, M., Department of Medical Oncology, Faculty of Medicine, Bezmialem University, Istanbul, Turkey

Subjects
Male, Chi-Square Distribution, Time Factors, Turkey, Prognostic Factors, Palliative Care, Kaplan-Meier Estimate, Adenocarcinoma, Middle Aged, Disease-Free Survival, Treatment Outcome, Risk Factors, Small Bowel Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Intestinal Neoplasms, Intestine, Small, Multivariate Analysis, Chemotherapy, Humans, Advanced, Female, Retrospective Studies
Abstract

WOS: 000388782200027 PubMed ID: 27837629 Purpose: Small bowel adenocarcinoma (SBA) is a rare tumor of the gastrointestinal system with poor prognosis. Since these are rarely encountered tumors, there are limited numbers of studies investigating systemic treatment in advanced SBA. The purpose of this study was to evaluate the prognostic factors and systemic treatments in patients with advance SBA. Methods: Seventy-one patients from 18 Centers with advanced SBA were included in the study. Fifty-six patients received one of the four different chemotherapy regimens as first-line therapy and 15 patients were treated with best supportive care (BSC). Results: Of the 71 patients, 42 (59%) were male and 29 (41%) female with a median age of 56 years. Median follow-up duration was 14.3 months. The median progression free survival (PFS) and overall survival (OS) were 7 and 13 months, respectively (N=71). In patients treated with FOLFOX (N=18), FOLFIRI (N=11), cisplatin-5-fluoroura-cil/5-FU (N=17) and gemcitabine alone (N=10), median PFS was 7, 8, 8 and 5 months, respectively, while median OS was 15, 16, 15 and 11 months, respectively. No significant differences between chemotherapy groups were noticed in terms of PFS and OS. Univariate analysis revealed that chemotherapy administration, de novo metastatic disease, ECOG PS 0 and 1, and overall response to therapy were significantly related to improved outcome. Only overall response to treatment was found to be significantly prognostic in multivariate analysis (p = 0.001). Conclusions: In this study, overall response to chemotherapy emerged as the single significant prognostic factor for advanced SBAs. Platin and irinotecan based regimens achieved similar survival outcomes in advanced SBA patients.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results